Validating Stat3 in cancer therapy
JE Darnell Jr - Nature medicine, 2005 - nature.com
JE Darnell Jr
Nature medicine, 2005•nature.comThe transcription factor STAT3 is overactive in many tumors and has attracted attention as a
drug target. But in vivo evidence suggesting that inhibiting STAT3 could counteract cancer
has been incomplete. The picture in the whole animal now begins to clarify, and it bodes
well for this approach (pages 623–629).
drug target. But in vivo evidence suggesting that inhibiting STAT3 could counteract cancer
has been incomplete. The picture in the whole animal now begins to clarify, and it bodes
well for this approach (pages 623–629).
The transcription factor STAT3 is overactive in many tumors and has attracted attention as a drug target. But in vivo evidence suggesting that inhibiting STAT3 could counteract cancer has been incomplete. The picture in the whole animal now begins to clarify, and it bodes well for this approach (pages 623–629).
nature.com